Navigation Links
Johnson & Johnson Reports 2014 Second-Quarter Results:
Date:7/15/2014

NEW BRUNSWICK, N.J., July 15, 2014 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced sales of $19.5 billion for the second quarter of 2014, an increase of 9.1% as compared to the second quarter of 2013.  Operational results increased 9.4% and the negative impact of currency was 0.3%.  Domestic sales increased 14.9%.  International sales increased 4.4%, reflecting operational growth of 5.0% and a negative currency impact of 0.6%.

Net earnings and diluted earnings per share for the second quarter of 2014 were $4.3 billion and $1.51, respectively.  The second-quarter results included a charge for after-tax special items of approximately $0.4 billion, primarily related to an increase in the litigation accrual as well as integration and transaction costs related to the acquisition of Synthes, Inc.  Second quarter 2013 net earnings included a charge for after-tax special items of approximately $0.5 billion as shown in the accompanying reconciliation of non-GAAP financial measures. Excluding these special items, net earnings for the current quarter were $4.8 billion and diluted earnings per share were $1.66, representing increases of 11.3% and 12.2%, respectively, as compared to the same period in 2013.*"Our strong second-quarter results reflect the continued success of our new product launches and the progress we have made in achieving our near-term priorities," said Alex Gorsky, Chairman and Chief Executive Officer.  "Significant advancements are being made in the treatment options and access to care for patients and customers around the world. Our diversified business model, focus on long-term growth drivers and talented colleagues position us well in this evolving and dynamic global health care market."

The Company increased its earnings guidance for full-year 2014 to $5.85 - $5.92 per share. The Company's guidance excludes the impact of special items.

Worldwide Consumer sales of $3.7 billion for the second quarter represented an increase of 2.4% versus the prior year consisting of an operational increase of 3.6% and a negative impact from currency of 1.2%.Domestic sales decreased 0.5% primarily reflecting the divestiture of the sanitary protection business. International sales increased 3.9%, which reflected an operational increase of 5.8% and a negative currency impact of 1.9%.

Positive contributors to operational results were sales of TYLENOL® and MOTRIN® analgesics; over-the-counter upper respiratory medicines as well as anti-smoking aids; NEUTROGENA® and AVEENO® skin care products; baby care products; and international sales of LISTERINE® mouthwash and feminine protection products.

Worldwide Pharmaceutical sales of $8.5 billion for the second quarter represented an increase of 21.1% versus the prior year on a total and operational basis.  Domestic sales increased 36.6%.  International sales increased 6.8% which reflected an operational increase of 6.9% and a negative currency impact of 0.1%. 

The strong sales results were primarily driven by new products including OLYSIO®/SOVRIAD® (simeprevir), for combination treatment of chronic hepatitis C in adult patients; XARELTO® (rivaroxaban), an oral anticoagulant; ZYTIGA® (abiraterone acetate), an oral, once-daily medication for use in combination with prednisone for the treatment of metastatic, castration-resistant prostate cancer; INVOKANA® (canagliflozin), for the treatment of adults with type 2 diabetes; and IMBRUVICA® (ibrutinib), a kinase inhibitor for the treatment of mantle cell lymphoma and chronic lymphocytic leukemia in patients who have had at least one prior therapy.

Additional contributors to operational sales growth were STELARA® (ustekinumab), a biologic approved for the treatment of moderate to severe plaque psoriasis and psoriatic arthritis; REMICADE® (infliximab) and SIMPONI®/SIMPONI® ARIA™ (golimumab), biologics approved for the treatment of a number of immune-mediated inflammatory diseases;  INVEGA®  SUSTENNA®/XEPLION® (paliperidone palmitate), a once-monthly, long-acting, injectable atypical antipsychotic for the treatment of schizophrenia in adults; and PREZISTA® (darunavir), a treatment for HIV.

Sales results were negatively impacted by loss of exclusivity for ACIPHEX® (rabeprazole), a proton pump inhibitor for gastrointestinal disorders, and CONCERTA® (methylphenidate HCI) for the treatment of attention deficit hyperactivity disorder.

During the quarter, the U.S. Food and Drug Administration (FDA) and the European Commission (EC) granted approval of SYLVANT® (siltuximab) for the treatment of patients with multicentric Castleman's disease who are human immunodeficiency virus negative and human herpesvirus-8 negative. In addition, the EC granted approval for VOKANAMET®, a fixed-dose therapy combining canagliflozin and immediate release metformin hydrochloride in a single tablet for the treatment of adults with type 2 diabetes; OLYSIO® (simeprevir) for the treatment of adult patients with genotype 1 or 4 chronic hepatitis C; and for INVEGA® (paliperidone ER) to extend its adult indication of schizophrenia to include adolescents aged 15 years and older.

In addition, a supplemental New Drug Application (sNDA) was submitted to the FDA seeking approval for simeprevir in combination with the nucleotide analog NS5B polymerase inhibitor sofosbuvir developed by Gilead Sciences, Inc.  Additional sNDA's were also submitted to the FDA for once-monthly atypical long-acting antipsychotic INVEGA® SUSTENNA® (paliperidone palmitate) for approval to treat schizoaffective disorder as either monotherapy or adjunctive therapy.

A Marketing Authorization Application was submitted to the European Medicines Agency to expand the label for VELCADE® (bortezomib) to include its use, in combination with rituximab, cyclophosphamide, doxorubicin and prednisone, for the treatment of adult patients with previously untreated mantle cell lymphoma.

Worldwide Medical Devices and Diagnostics sales of $7.2 billion for the second quarter represented an increase of 0.7% versus the prior year consisting of an operational increase of 0.9% and a negative currency impact of 0.2%.  Domestic sales decreased 1.4%.  International sales increased 2.3%, which reflected an operational increase of 2.6% and a negative currency impact of 0.3%.

Primary contributors to operational growth were hip and trauma products in the Orthopaedics business, Biosense Webster's electrophysiology products in the Cardiovascular Care business, and sales of energy products in the Specialty Surgery business.

Sales results in the U.S. Diabetes Care business were negatively impacted by price declines associated with the implementation of Medicare competitive bidding in mail order and retail effective July 1, 2013.

During the quarter, the SABER™ PTA Dilatation Catheter for the treatment of patients with Peripheral Arterial Disease received FDA and EC approval.

Subsequent to the quarter, on June 30, the Company completed the divestiture of its Ortho-Clinical Diagnostics business to The Carlyle Group for approximately $4 billion, subject to customary adjustments.

About Johnson & JohnsonCaring for the world, one person at a time, inspires and unites the people of Johnson & Johnson. We embrace research and science - bringing innovative ideas, products and services to advance the health and well-being of people. Our approximately 126,000 employees at more than 270 Johnson & Johnson operating companies work with partners in health care to touch the lives of over a billion people every day, throughout the world.

* Net earnings and diluted earnings per share excluding special items are non-GAAP financial measures and should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures. A reconciliation of these non-GAAP financial measures to the most directly comparable GAAP financial measures can be found in the accompanying financial schedules of the earnings release and the Investor Relations section of the Company's website at www.investor.jnj.com.

Johnson & Johnson will conduct a conference call with investors to discuss this news release today at 8:30 a.m., Eastern Time. A simultaneous webcast of the call for investors and other interested parties may be accessed by visiting the Johnson & Johnson website at www.investor.jnj.com. A replay and podcast will be available approximately two hours after the live webcast by visiting www.investor.jnj.com

Copies of the financial schedules accompanying this press release are available at www.investor.jnj.com/historical-sales.cfm.  These schedules include supplementary sales data, a condensed consolidated statement of earnings, reconciliation of non-GAAP financial measures, and sales of key products/franchises.  Additional information on Johnson & Johnson, including a pharmaceutical pipeline of selected compounds in late stage development and a copy of today's earnings call presentation can be found on the Company's website at www.investor.jnj.com.

NOTE TO INVESTORS

(This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to, economic factors, such as interest rate and currency exchange rate fluctuations; competition, including technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; the impact of patent expirations; challenges to patents; significant adverse litigation or government action, including related to product liability claims; impact of business combinations and divestitures; changes in behavior and spending patterns or financial distress of purchasers of health care products and services; changes to governmental laws and regulations and domestic and foreign health care reforms; trends toward health care cost containment; increased scrutiny of the health care industry by government agencies; financial instability of international economies and sovereign risk; disruptions due to natural disasters; manufacturing difficulties or delays, internally or within the supply chain; complex global supply chains with increasing regulatory requirements; and product efficacy or safety concerns resulting in product recalls or regulatory action. A further list and description of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 29, 2013, including Exhibit 99 thereto, and the company's subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.investor.jnj.com or on request from Johnson & Johnson. Any forward-looking statement made in this release speaks only as of the date on which it is made. Johnson & Johnson does not undertake to update any forward-looking statements as a result of new information or future events or developments.)

 Johnson & Johnson and SubsidiariesSupplementary Sales Data(Unaudited; Dollars in Millions)SECOND QUARTERSIX MONTHSPercent ChangePercent Change20142013TotalOperationsCurrency20142013TotalOperationsCurrencySales to customers bysegment of businessConsumerU.S.$   1,3201,326(0.5)

%

(0.5)-$   2,6292,674(1.7)

%

(1.7)-International2,4242,3323.95.8(1.9)4,6724,6590.33.3(3.0)3,7443,6582.43.6(1.2)7,3017,333(0.4)1.5(1.9)PharmaceuticalU.S.4,6133,37736.636.6-8,3536,84822.022.0-International3,8963,6486.86.9(0.1)7,6546,94510.211.6(1.4)8,5097,02521.121.10.016,00713,79316.116.8(0.7)Med Devices & DiagnosticsU.S.3,1993,243(1.4)(1.4)-6,3546,449(1.5)(1.5)-International4,0433,9512.32.6(0.3)7,9487,8071.83.6(1.8)7,2427,1940.70.9(0.2)14,30214,2560.31.3(1.0)U.S.9,1327,94614.914.9-17,33615,9718.58.5-International10,3639,9314.45.0(0.6)20,27419,4114.46.4(2.0)Worldwide$ 19,49517,8779.1

%

9.4(0.3)$ 37,61035,3826.3

%

7.4(1.1) Johnson & Johnson and SubsidiariesSupplementary Sales Data(Unaudited; Dollars in Millions)SECOND QUARTERSIX MONTHSPercent ChangePercent Change20142013TotalOperationsCurrency20142013TotalOperationsCurrencySales to customers bygeographic areaU.S.

$   9,1327,94614.9

%

14.9-$ 17,33615,9718.5

%

8.5-Europe

5,0564,6728.24.14.19,9419,1538.65.33.3Western Hemisphere excluding U.S.

1,8631,905(2.2)6.5(8.7)3,5583,688(3.5)6.8(10.3)Asia-Pacific, Africa

3,4443,3542.75.3(2.6)6,7756,5703.17.7(4.6)International

10,3639,9314.45.0(0.6)20,27419,4114.46.4(2.0)Worldwide

$ 19,49517,8779.1

%

9.4(0.3)$ 37,61035,3826.3

%

7.4(1.1) Johnson & Johnson and SubsidiariesCondensed Consolidated Statement of Earnings (Unaudited; in Millions Except Per Share Figures)SECOND QUARTER20142013PercentPercentPercentIncreaseAmountto SalesAmountto Sales(Decrease)Sales to customers$ 19,495100.0$ 17,877100.09.1Cost of products sold6,03931.05,48930.710.0Selling, marketing and administrative expenses5,48128.15,37630.12.0Research and development expense2,00510.31,94610.93.0In-process research and development40.0--Interest (income) expense, net1140.61010.6Other (income) expense, net2261.11720.9Earnings before provision for taxes on income5,62628.94,79326.817.4Provision for taxes on income1,3006.79605.435.4Net earnings$   4,32622.2$   3,83321.412.9Net earnings per share (Diluted)$
.51
$
.33
13.5Average shares outstanding (Diluted)2,874.22,893.0Effective tax rate23.1

%20.0

%Adjusted earnings before provision for taxes and net earnings (1)Earnings before provision for taxes on income$   6,05031.0$   5,35930.012.9Net earnings$   4,77524.5$   4,28924.011.3Net earnings per share (Diluted)$
.66
$
.48
12.2Effective tax rate21.1

%20.0

%(1) See Reconciliation of Non-GAAP Financial Measures. Johnson & Johnson and SubsidiariesCondensed Consolidated Statement of Earnings (Unaudited; in Millions Except Per Share Figures)SIX MONTHS20142013PercentPercentPercentIncreaseAmountto SalesAmountto Sales(Decrease)Sales to customers$ 37,610100.0$ 35,382100.06.3Cost of products sold11,49430.611,04331.24.1Selling, marketing and administrative expenses10,66428.310,59930.00.6Research and development expense3,83610.23,73010.52.8In-process research and development220.1640.2Interest (income) expense, net2320.62050.6Other (income) expense, net3120.86871.9Earnings before provision for taxes on income11,05029.49,05425.622.0Provision for taxes on income1,9975.31,7244.915.8Net earnings$   9,05324.1$   7,33020.723.5Net earnings per share (Diluted)$
3.15
$
2.55
23.5Average shares outstanding (Diluted)2,875.52,878.8Effective tax rate18.1

%19.0

%Adjusted earnings before provision for taxes and net earnings (1)Earnings before provision for taxes on income$ 11,61030.9$ 10,42929.511.3Net earnings$   9,20124.5$   8,39623.79.6Net earnings per share (Diluted)$
3.20
$
2.92
9.6Effective tax rate20.7

%19.5

%(1) See Reconciliation of Non-GAAP Financial Measures. 

 Johnson & Johnson and SubsidiariesReconciliation of Non-GAAP Financial MeasuresSecond Quarter% Incr. /Six Months YTD% Incr. /(Dollars in Millions Except Per Share Data)

20142013(Decr.)20142013(Decr.)Earnings before provision for taxes on income - as reported

$ 5,6264,79317.4

%$ 11,0509,05422.0

%Litigation expenses

276375276904Synthes integration/transaction costs 

144122262380In-process research and development

4-2264DePuy ASRHip program

-69-82Other

---(55)Earnings before provision for taxes on income - as adjusted

$ 6,0505,35912.9

%$ 11,61010,42911.3

%Net Earnings - as reported

$ 4,3263,83312.9

%$   9,0537,33023.5

%Litigation expenses

342

(1)

308342699Synthes integration/transaction costs 

10487188270In-process research and development

3-1642DePuy ASRHip program

-61-91Tax benefit associated with Conor Medsystems

--(398)-Other

---(36)Net Earnings - as adjusted 

$ 4,7754,28911.3

%$   9,2018,3969.6

%Diluted Net Earnings per share - as reported

$   1.511.3313.5

%$
3.15
2.5523.5

%Litigation expenses

0.120.100.120.24Synthes integration/transaction costs

0.030.030.060.09In-process research and development

--0.010.02DePuy ASRHip program

-0.02-0.03Tax benefit associated with Conor Medsystems

--(0.14)-Other

---(0.01)Diluted Net Earnings per share - as adjusted 

$   1.661.4812.2

%$
3.20
2.929.6

%(1) Includes adjustment to deferred tax asset related to deductibility by tax jurisdictionThe Company believes investors gain additional perspective of underlying business trends and results by providing a measure of earnings before provision for taxes on income, net earnings and diluted net earnings per share that excludes special items in order to evaluate ongoing business operations. 

 REPORTED SALES vs. PRIOR PERIOD ($MM)SECOND QUARTERSIX MONTHS% Change% Change20142013ReportedOperational (1)Currency20142013ReportedOperational (1)CurrencyCONSUMER SEGMENT (2)BABY CAREUS$
7
106

0.9%

0.9%

-$
209
209

0.0%

0.0%

-Intl500480

4.2%

8.6%

-4.4%943941

0.2%

5.5%

-5.3%WW607586

3.6%

7.2%

-3.6%1,1521,150

0.2%

4.6%

-4.4%ORAL CAREUS142149

-4.7%

-4.7%

-302307

-1.6%

-1.6%

-Intl271257

5.4%

7.3%

-1.9%522502

4.0%

7.2%

-3.2%WW413406

1.7%

2.9%

-1.2%824809

1.9%

3.9%

-2.0%OTCUS316290

9.0%

9.0%

-682644

5.9%

5.9%

-Intl687641

7.2%

7.4%

-0.2%1,3321,330

0.2%

1.7%

-1.5%WW1,003931

7.7%

7.8%

-0.1%2,0141,974

2.0%

3.0%

-1.0%SKIN CAREUS506463

9.3%

9.3%

-963916

5.1%

5.1%

-Intl462445

3.8%

4.2%

-0.4%919894

2.8%

4.4%

-1.6%WW968908

6.6%

6.8%

-0.2%1,8821,810

4.0%

4.8%

-0.8%WOMEN'S HEALTHUS1184

-86.9%

-86.9%

-35165

-78.8%

-78.8%

-Intl331327

1.2%

5.4%

-4.2%634647

-2.0%

3.3%

-5.3%WW342411

-16.8%

-13.5%

-3.3%669812

-17.6%

-13.4%

-4.2%WOUND CARE/OTHERUS238234

1.7%

1.7%

-438433

1.2%

1.2%

-Intl173182

-4.9%

-4.4%

-0.5%322345

-6.7%

-5.4%

-1.3%WW411416

-1.2%

-1.0%

-0.2%760778

-2.3%

-1.7%

-0.6%TOTAL CONSUMERUS1,3201,326

-0.5%

-0.5%

-2,6292,674

-1.7%

-1.7%

-Intl2,4242,332

3.9%

5.8%

-1.9%4,6724,659

0.3%

3.3%

-3.0%WW$ 3,7443,658

2.4%

3.6%

-1.2%$   7,3017,333

-0.4%

1.5%

-1.9%See footnotes at end of schedule REPORTED SALES vs. PRIOR PERIOD ($MM)SECOND QUARTERSIX MONTHS% Change% Change20142013ReportedOperational (1)Currency20142013ReportedOperational (1)CurrencyPHARMACEUTICAL SEGMENT (2) (3)IMMUNOLOGYUS$ 1,8531,578

17.4%

17.4%

-$   3,4003,217

5.7%

5.7%

-Intl778663

17.3%

19.1%

-1.8%1,5741,228

28.2%

31.8%

-3.6%WW2,6312,241

17.4%

17.9%

-0.5%4,9744,445

11.9%

12.9%

-1.0%REMICADEUS 1,021926

10.3%

10.3%

-2,0181,896

6.4%

6.4%

-US Exports (4)357332

7.5%

7.5%

-524681

-23.1%

-23.1%

-Intl426414

2.9%

6.3%

-3.4%872695

25.5%

31.0%

-5.5%WW1,8041,672

7.9%

8.7%

-0.8%3,4143,272

4.3%

5.5%

-1.2%SIMPONI/SIMPONI ARIAUS13287

51.7%

51.7%

-236181

30.4%

30.4%

-Intl15088

70.5%

71.3%

-0.8%305231

32.0%

34.7%

-2.7%WW282175

61.1%

61.5%

-0.4%541412

31.3%

32.8%

-1.5%STELARAUS343233

47.2%

47.2%

-622459

35.5%

35.5%

-Intl185138

34.1%

31.4%

2.7%362258

40.3%

39.2%

1.1%WW528371

42.3%

41.3%

1.0%984717

37.2%

36.8%

0.4%OTHER IMMUNOLOGYUS--

-

-

---

-

-

-Intl1723

-26.1%

-22.7%

-3.4%3544

-20.5%

-14.6%

-5.9%WW1723

-26.1%

-22.7%

-3.4%3544

-20.5%

-14.6%

-5.9%INFECTIOUS DISEASESUS1,020259

*

*

-1,581497

*

*

-Intl742711

4.4%

3.5%

0.9%1,3811,288

7.2%

6.6%

0.6%WW1,762970

81.6%

80.9%

0.7%2,9621,785

65.9%

65.5%

0.4%EDURANTUS63

100.0%

100.0%

-116

83.3%

83.3%

-Intl8653

62.3%

57.7%

4.6%16293

74.2%

70.3%

3.9%WW9256

64.3%

60.0%

4.3%17399

74.7%

71.0%

3.7%INCIVOUS--

-

-

---

-

-

-Intl97172

-43.6%

-42.5%

-1.1%183334

-45.2%

-44.8%

-0.4%WW97172

-43.6%

-42.5%

-1.1%183334

-45.2%

-44.8%

-0.4%OLYSIO/SOVRIADUS725-

*

*

-1,016-

*

*

-Intl106-

*

*

0.0%169-

*

*

0.0%WW831-

*

*

0.0%1,185-

*

*

0.0%PREZISTAUS239196

21.9%

21.9%

-453363

24.8%

24.8%

-Intl253239

5.9%

4.7%

1.2%484439

10.3%

9.6%

0.7%WW492435

13.1%

12.4%

0.7%937802

16.8%

16.4%

0.4%OTHER INFECTIOUS DISEASESUS5060

-16.7%

-16.7%

-101128

-21.1%

-21.1%

-Intl200247

-19.0%

-19.6%

0.6%383422

-9.2%

-9.0%

-0.2%WW250307

-18.6%

-19.0%

0.4%484550

-12.0%

-11.9%

-0.1% REPORTED SALES vs. PRIOR PERIOD ($MM)SECOND QUARTERSIX MONTHS% Change% Change20142013ReportedOperational (1)Currency20142013ReportedOperational (1)CurrencyNEUROSCIENCEUS600626

-4.2%

-4.2%

-1,2011,372

-12.5%

-12.5%

-Intl1,0271,054

-2.6%

-2.4%

-0.2%2,0642,052

0.6%

2.5%

-1.9%WW1,6271,680

-3.2%

-3.1%

-0.1%3,2653,424

-4.6%

-3.5%

-1.1%CONCERTA/METHYLPHENIDATEUS2885

-67.1%

-67.1%

-63224

-71.9%

-71.9%

-Intl117130

-10.0%

-8.3%

-1.7%232247

-6.1%

-3.0%

-3.1%WW145215

-32.6%

-31.6%

-1.0%295471

-37.4%

-35.8%

-1.6%INVEGAUS8976

17.1%

17.1%

-175147

19.0%

19.0%

-Intl6974

-6.8%

-7.5%

0.7%148135

9.6%

11.3%

-1.7%WW158150

5.3%

5.0%

0.3%323282

14.5%

15.3%

-0.8%INVEGA SUSTENNA/ XEPLIONUS202158

27.8%

27.8%

-384322

19.3%

19.3%

-Intl192132

45.5%

42.3%

3.2%383252

52.0%

51.0%

1.0%WW394290

35.9%

34.4%

1.5%767574

33.6%

33.2%

0.4%RISPERDAL CONSTAUS110107

2.8%

2.8%

-216213

1.4%

1.4%

-Intl192229

-16.2%

-17.7%

1.5%396458

-13.5%

-13.4%

-0.1%WW302336

-10.1%

-11.1%

1.0%612671

-8.8%

-8.7%

-0.1%OTHER NEUROSCIENCEUS171200

'/>"/>

SOURCE Johnson & Johnson
Copyright©2014 PR Newswire.
All rights reserved


Related medicine technology :

1. Adaptive Announces a Biomarker Discovery Agreement with Johnson & Johnson Innovation
2. Janssen Pharmaceutical Companies of Johnson & Johnson Submit Citizen Petition to the U.S. FDA Regarding Naming of Biosimilars
3. Healthcare Companies Report Stock Price Updates, and Medical System Integration - Research Report on Johnson & Johnson, Geron, Ligand Pharmaceuticals, Masimo, and Capital Senior Living
4. Janssen, the Pharmaceutical Companies of Johnson & Johnson, Announces First-of-its-Kind Drug Donation Program for HIV Treatment-Experienced Children
5. Johnson & Johnson Settlement Resolves Metal Hip Lawsuits But Weak Oversight Of Medical Device Industry Leaves Hundreds of Thousands of Patients Vulnerable
6. KV Pharmaceutical Company Completes New Board with Appointment of Former Johnson & Johnson Executive
7. Legal Actions, Quarterly Dividends, Collaborations, and New Appointments - Research Report on Johnson & Johnson, Zoetis, Abbott, Teva Pharmaceuticals, and Baxter
8. Johnson & Johnson Completes Acquisition Of Aragon Pharmaceuticals, Inc.
9. Johnson & Johnson Reports 2013 Second-Quarter Results:
10. Johnson & Johnson Announces Definitive Agreement To Acquire Aragon Pharmaceuticals, Inc.
11. Janssen and Johnson & Johnson to Provide Webcast Presentation of Simeprevir Phase 3 Clinical Data Presented at The International Liver Congress of the European Association for the Study of the Liver (EASL)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... 2016  Aralez Pharmaceuticals Inc. ("Aralez") today announced the ... Tribute Pharmaceuticals Canada Inc. ("Tribute") following approval of the ... The combined company will operate under Aralez Pharmaceuticals Inc. ... Canada , Ireland ... Under the terms of the Agreement and Plan of ...
(Date:2/5/2016)... New York , February 5, 2016 ... new Transparency Market Research report states that the global ... in 2014 and is predicted to reach US$185.9 bn ... CAGR of 6.50% from 2014 to 2020. The title ... (Branded/Generic/Over-the-counter, Chemical/Biological, Captive/Contract Manufactured, by Geography, and by Therapeutic ...
(Date:2/5/2016)... -- Henry Schein, Inc. (NASDAQ: HSIC ), the world,s largest ... dental, animal health and medical practitioners, announced today that ... majority ownership interest in Dental Cremer S.A., a distributor ... . --> ... dental distribution business of Cremer S.A. With 2015 sales ...
Breaking Medicine Technology:
(Date:2/5/2016)... , ... February 05, 2016 , ... US Sports ... Studio in Dover, NH to direct high-performance kids yoga training. ChildLight Yoga Studio is ... just one hour from Boston. , ChildLight Yoga Studio founder Lisa Flynn expresses her ...
(Date:2/5/2016)... (PRWEB) , ... February 05, 2016 , ... The American ... technology, such water may be safer than regular municipal or well water. The recent ... radio host Sharon Kleyne, could go a long way toward increasing public acceptance of ...
(Date:2/5/2016)... , ... February 05, 2016 , ... Give To ... users to search for and donate to Give To Cure’s campaign that is crowdfunding ... that lets users make and share payments through a smart device. In 2015 alone, ...
(Date:2/5/2016)... ... February 05, 2016 , ... Pivot Point ... Best in KLAS: Software & Services for HIT Implementation Support & Staffing report ... independently ranks vendor performance by healthcare executives, managers and clinicians representing over 4,500 ...
(Date:2/5/2016)... ... 05, 2016 , ... Dr. Justin Scott and Dr. Lydia Muccioli of ... Day to individuals in need. The event is scheduled to take place on February ... is to provide dental care to community members in need. Each patient will be ...
Breaking Medicine News(10 mins):